Novavax, Inc.

Healthcare

NASDAQ:NVAX · NASDAQ Global Select

Market Cap $1.41B Beta 2.41 P/E (TTM) -16.5

$8.88 -1.66%

-$0.15 today

52W Low $6.13High $11.97

Vol 2.59M · Avg 4.65M

EPS (TTM)-$0.54

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+27.95%

Period High

$11.19

Period Low

$6.22

Latest

$8.88

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Terns Pharmaceuticals, Inc.

TERN

$4.77B

Trevi Therapeutics, Inc.

NASDAQ:TRVI

$2.02B

Intellia Therapeutics, Inc.

NASDAQ:NTLA

$1.36B

Precigen, Inc.

NASDAQ:PGEN

$1.34B

Nektar Therapeutics

NASDAQ:NKTR

$1.16B

Wave Life Sciences Ltd.

NASDAQ:WVE

$1.13B

CureVac N.V.

CVAC

$1.05B

Zenas BioPharma, Inc.

NASDAQ:ZBIO

$883.93M

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$856.09M

Upstream Bio, Inc.

UPB

$331.96M

What is the latest NVAX filing?

The latest filing shown is SC 13D/A dated May 15, 2026.

How many recent filings does NVAX have?

Intrinsic Alpha currently shows 20 recent filings for NVAX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.